Mechanisms of resistance to immune checkpoint inhibitors

Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are rapidly transforming the practice of medical oncology. Whereas cytotoxic chemotherapy and small molecule inhibitors ('targeted therapies'...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of cancer Ročník 118; číslo 1; s. 9
Hlavní autoři:	Jenkins, Russell W, Barbie, David A, Flaherty, Keith T
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Nature Publishing Group 01.01.2018
Témata:	Animals Biomarkers Cancer Chemotherapy CTLA-4 protein Cytotoxicity Drug Resistance, Neoplasm Humans Immune checkpoint inhibitors Immune response Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Immunotherapy Lymphocytes T Molecular Targeted Therapy Neoplasms - drug therapy Neoplasms - immunology PD-1 protein PD-L1 protein Signal Transduction - drug effects T-Lymphocytes - drug effects Tumors
ISSN:	0007-0920, 1532-1827, 1532-1827
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!